Celadon Pharmaceuticals Plc (CEL.L) Research

Celadon Pharmaceuticals Plc functions as a drug development company, concentrating on the discovery, production, and distribution of cannabinoid compounds for certified medical uses. The firm's primary activity involves the indoor, hydroponic cultivation of THC cannabis, which is then incorporated into medicinal products targeting chronic pain. Furthermore, Celadon intends to broaden its research into cannabinoids, exploring their therapeutic applications not only for persistent pain but also for conditions such as autism and multiple sclerosis. Established in 2018, the company maintains its headquarters in London, United Kingdom.

Market snapshot

Symbol
CEL.L
Price
$13.40
Day change
+16.52%
Market cap
$9.2M
P/E ratio
-1.16x
52-week range
0.06-83
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Peer companies

  • Advanced Oncotherapy plc (AVO.L)
  • BiVictriX Therapeutics Plc (BVX.L)
  • Cambridge Nutritional Sciences plc (CNSL.L)
  • Hellenic Dynamics Plc (HELD.L)
  • Induction Healthcare Group PLC (INHC.L)
  • MGC Pharmaceuticals Limited (MXC.L)
  • NetScientific plc (NSCI.L)
  • Argent BioPharma Limited (RGT.L)

Open Celadon Pharmaceuticals Plc (CEL.L) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.